

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method of inhibiting osteoclast-mediated bone resorption in a bone cell, comprising inhibiting an activity of a gene product encoded by osteoclast associated gene OC14 comprising the nucleotide sequence of SEQ ID NO: 50 by administering ~~a compound~~ an antibody that decreases the activity of said gene product by at least 10% in the presence of said ~~compound antibody~~, as compared to the activity of said gene product in the absence of said ~~compound antibody~~, and wherein ~~said compound is an antibody or an antisense polynucleotide~~.

2. - 26. (Cancelled)

27. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 1.5-fold in the presence of said ~~compound antibody~~, as compared to the activity of said gene product in the absence of said ~~compound antibody~~.

28. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 3-fold in the presence of said ~~compound antibody~~, as compared to the activity of said gene product in the absence of said ~~compound antibody~~.

29. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 5-fold in the presence of said ~~compound antibody~~, as compared to the activity of said gene product in the absence of said ~~compound antibody~~.

30. (Cancelled)

31. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 50% in the presence of said ~~compound antibody~~, as compared to the activity of said gene product in the absence of said ~~compound antibody~~.

32. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 75% in the presence of said ~~compound antibody~~, as compared to the activity of said gene product in the absence of said ~~compound antibody~~.

33. (Currently Amended) The method of claim 1, wherein the activity of said gene product is decreased by at least 90% in the presence of said ~~compound antibody~~, as compared to the activity of said gene product in the absence of said ~~compound antibody~~.